PML and FOS

  • Number of citations of the paper that reports this interaction (PMID 9671405)
  • 14

PML

FOS

Gene Name promyelocytic leukemia FBJ murine osteosarcoma viral oncogene homolog
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9 108 interactors: ANP32E APP AQP1 ARFGAP1 ARL6IP4 ATF2 ATF3 ATF4 ATF7 ATP5I BATF BCL3 CABP1 CARM1 CEBPA CEBPE CEBPG CENPO CFAP57 CLU COPS4 CREB5 CREBBP CSNK2A1 CSNK2A2 CYTH4 DDIT3 EEF1D ELK1 ELK4 EPHB2 ETS1 ETS2 GAMT GATA4 GLB1 GNG11 GRHPR GTF2E2 GTF2F1 GTF2F2 HNF1A HSPA1A JUN JUNB JUND KDM2A LMNA LMO3 LUZP4 MAF MAFB MAFF MAP1B MAP3K7 MAPK1 MAPK7 MITF MTERF4 NACA NCOA1 NCOA2 NCOA3 NCOA6 NCOR2 NEFM NELFB NFATC3 NFKB1 OPTN PML POLR2E PRKAA2 PRKACA PSMC5 RB1 RELA RPS6KA1 RPS6KA2 RPS6KA4 RUNX1 RUNX2 SCHIP1 SET SIRT1 SMAD3 SMARCD1 SPI1 SRA1 STAT1 SUMO1 SUMO2 SUMO3 SUMO4 TAF1 TBP TRO TSC22D3 TSPAN2 UBE2D1 UBE2I UBE2L3 UBR1 USF1 USF2 VDR XBP1 ZNF133
Entrez ID 5371 2353
HPRD ID 00023 01275
Ensembl ID ENSG00000140464 ENSG00000170345
Uniprot IDs P29590 B4DQ65 P01100 Q6FG41
PDB IDs 1BOR 1A02 1FOS 1S9K
Enriched GO Terms of Interacting Partners?
Tagcloud ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
ap  argue  capable  dimeric  dimerization  disrupt  glucocorticoid  heterodimerization  homo  homodimerization  hraralpha  hybrid  indirect  interfere  jun  liganded  occurring  promoters  protooncoproteins  ra  raralpha  rars  repress  repression  responsive  retinoic  retinoid  rxr  rxrs 
Tagcloud (Difference) ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  rar  recruit  refinement  relapsed  safe  timed  trioxide  vast 
ap  argue  capable  dimeric  dimerization  disrupt  glucocorticoid  heterodimerization  homo  homodimerization  hraralpha  hybrid  indirect  interfere  jun  liganded  occurring  protooncoproteins  raralpha  rars  repress  responsive  retinoic  retinoid  rxr  rxrs 
Tagcloud (Intersection) ?
promoters  ra  repression